• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Clover Health Investments Corp. (Amendment)

    1/14/22 4:30:17 PM ET
    $CLOV
    Medical Specialities
    Health Care
    Get the next $CLOV alert in real time by email
    SC 13D/A 1 sc13da1.htm SCHEDULE 13D, AMENDMENT NO. 1
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13D

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    CLOVER HEALTH INVESTMENTS, CORP.
    (Name of Issuer)

    Class A Common Stock
    (Title of Class of Securities)

    18914F111
    (CUSIP Number)

    Chamath Palihapitiya
    SCH Sponsor III LLC
    317 University Ave, Suite 200
    Palo Alto, California 94301
    (650) 521-9007
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    with copies to:

    Gregg A. Noel
    Skadden, Arps, Slate, Meagher & Flom LLP
    One Manhattan West
    New York, New York 10001-8602
    (212) 735-3000

    July 7, 2021
    (Date of Event Which Requires Filing of This Statement)
     
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐
     
     
    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.
     
     
     
    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     
     

             
    CUSIP No. 18914F111
      
     
      
    Page 2 of 9 pages
     
                 
      1.  
     
      Name of Reporting Person
     
      SCH Sponsor III LLC
      2.
     
      Check the Appropriate Box if a Member of a Group
      (a)  ☐        (b)  ⌧
     
      3.
     
      SEC Use Only
     
      4.
     
      Source of Funds
     
      WC
      5.
     
      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
     
      ☐
      6.
     
      Citizenship or Place of Organization
     
      Cayman Islands
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With
     
      
      7.  
      
      Sole Voting Power
     
      0
      
      8.
      
      Shared Voting Power
     
      0
      
      9.
      
      Sole Dispositive Power
     
      0
      
    10.
      
      Shared Dispositive Power
     
      0
    11.  
     
      Aggregate Amount Beneficially Owned by Each Reporting Person
     
      0
    12.
     
      Check if the Aggregate Amount in Row (11) Excludes Certain Shares
     
      ☐
    13.
     
      Percent of Class Represented by Amount in Row (11)
     
      0.0%
    14.
     
      Type of Reporting Person
     
      OO



    CUSIP No. 18914F111
      
     
      
    Page 3 of 9 pages
     
                 
      1.  
     
      Name of Reporting Person
     
      ChaChaCha SPAC C LLC
      2.
     
      Check the Appropriate Box if a Member of a Group
      (a)  ☐        (b)  ⌧
     
      3.
     
      SEC Use Only
     
      4.
     
      Source of Funds
     
      WC, BK
      5.
     
      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
     
      ☐
      6.
     
      Citizenship or Place of Organization
     
      Cayman Islands
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With
     
      
      7.  
      
      Sole Voting Power
     
      28,408,480
      
      8.
      
      Shared Voting Power
     
      0
      
      9.
      
      Sole Dispositive Power
     
      28,408,480
      
    10.
      
      Shared Dispositive Power
     
      0
    11.  
     
      Aggregate Amount Beneficially Owned by Each Reporting Person
     
      28,408,480
    12.
     
      Check if the Aggregate Amount in Row (11) Excludes Certain Shares
     
      ☐
    13.
     
      Percent of Class Represented by Amount in Row (11)
     
      8.6%
    14.
     
      Type of Reporting Person
     
      OO




             
    CUSIP No. 18914F111
      
     
      
    Page 4 of 9 pages
     
                 
      1.  
     
      Name of Reporting Person
     
      Chamath Palihapitiya
      2.
     
      Check the Appropriate Box if a Member of a Group
      (a)  ☐        (b)  ⌧
     
      3.
     
      SEC Use Only
     
      4.
     
      Source of Funds
     
      WC, BK
      5.
     
      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
     
      ☐
      6.
     
      Citizenship or Place of Organization
     
      United States
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With
     
      
      7.  
      
      Sole Voting Power
     
      30,432,501
      
      8.
      
      Shared Voting Power
     
      0
      
      9.
      
      Sole Dispositive Power
     
      30,432,501
      
    10.
      
      Shared Dispositive Power
     
      0
    11.  
     
      Aggregate Amount Beneficially Owned by Each Reporting Person
     
      30,432,501
    12.
     
      Check if the Aggregate Amount in Row (11) Excludes Certain Shares
     
      ☐
    13.
     
      Percent of Class Represented by Amount in Row (11)
     
      9.2%
    14.
     
      Type of Reporting Person
     
      IN




             
    CUSIP No. 18914F111
      
     
      
    Page 5 of 9 pages
     
                 
      1.  
     
      Name of Reporting Person
     
      Ian Osborne
      2.
     
      Check the Appropriate Box if a Member of a Group
      (a)  ☐        (b)  ⌧
     
      3.
     
      SEC Use Only
     
      4.
     
      Source of Funds
     
      WC
      5.
     
      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
     
      ☐
      6.
     
      Citizenship or Place of Organization
     
      United Kingdom
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person
    With
     
      
      7.  
      
      Sole Voting Power
     
      4,063,919
      
      8.
      
      Shared Voting Power
     
      0
      
      9.
      
      Sole Dispositive Power
     
      4,063,919
      
    10.
      
      Shared Dispositive Power
     
      0
    11.  
     
      Aggregate Amount Beneficially Owned by Each Reporting Person
     
      4,063,919
    12.
     
      Check if the Aggregate Amount in Row (11) Excludes Certain Shares
     
      ☐
    13.
     
      Percent of Class Represented by Amount in Row (11)
     
      1.2%
    14.
     
      Type of Reporting Person
     
      IN




     
    EXPLANATORY NOTE
    Item 1. Security and Issuer
    This Amendment No. 1 to Schedule 13D amends and supplements the Schedule 13D filed with the United States Securities and Exchange Commission on January 15, 2021 (the “Schedule 13D”) relating to the Class A common stock, par value $0.0001 per share (the “Class A Common Stock”), of Clover Health Investments, Corp., a Delaware corporation (the “Issuer”), whose principal executive offices are located at 3401 Mallory Lane, Suite 210, Franklin, Tennessee 37067.
    Item 2. Identity and Background

    Item 2 of the Schedule 13D is hereby amended and restated as follows:

    SCH Sponsor III LLC, a Cayman Islands limited liability company (the “Sponsor”), ChaChaCha SPAC C LLC, a Delaware limited liability company ("ChaChaCha"), Chamath Palihapitiya, a citizen of the United States, and Ian Osborne, a citizen of the United Kingdom (each, a “Reporting Person” and, collectively, the “Reporting Persons”).

    The principal business address of each of SCH Sponsor III LLC, ChaChaCha and Mr. Palihapitiya is 317 University Avenue, Suite 200, Palo Alto, California 94301.  The principal business address of Mr. Osborne is Roseneath, The Grange, St. Peter Port, Guernsey GY1 2QJ.
    During the last five years, none of the Reporting Persons (i) has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    Item 3. Source and Amount of Funds or Other Consideration

    Item 3 of the Schedule 13D is hereby amended and supplemented by the following:

    The information set forth in Item 5(c) of the Schedule 13D is incorporated herein by reference.

    On January 7, 2021, an affiliate of Mr. Palihapitiya initially received 284,891 shares of Class B common stock, $0.0001 per share (the “Class B Common Stock”), of the Issuer in connection with the closing of the Business Combination.  The Class B Common Stock has ten votes per share and is convertible into shares of Class A Common Stock on a one-for-one basis.

    Item 5. Interest in Securities of the Issuer
    Item 5 of the Schedule 13D is hereby amended and restated as follows:
    (a) – (b)
    The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Class A Common Stock and percentage of Class A Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Class A Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 330,482,877 shares of Class A Common Stock outstanding after the closing of the Offering (as defined below) on November 22, 2021:



     
                                                     
    Reporting Person(1)
      
    Amount
    beneficially
    owned
     
      
    Percent
    of class
     
     
    Sole
    power to
    vote or to
    direct the
    vote
     
      
    Shared
    power to
    vote or to
    direct the
    vote
     
      
    Sole power
    to dispose or
    to direct
    the
    disposition
     
      
    Shared
    power to
    dispose or to
    direct the
    disposition
     
    SCH Sponsor III LLC
      
     
    0
     
      
     
    0.0
    % 
     
     
    0
     
      
     
    0
     
      
     
    0
     
      
     
    0
     
    ChaChaCha SPAC C LLC
       
    28,408,480
         
    8.6
    %
       
    28,408,480
         
    0
         
    28,408,480
         
    0
     
    Chamath Palihapitiya(1)
      
     
    30,432,501
     
      
     
    9.2
    % 
     
     
    30,432,501
     
      
     
    0
     
      
     
    30,432,501
     
      
     
    0
     
    Ian Osborne
      
     
    4,063,919
     
      
     
    1.2
    % 
     
     
    4,063,919
     
      
     
    0
     
      
     
    4,063,919
     
      
     
    0
     

    (1) Mr. Palihapitiya may be deemed to beneficially own the Issuer securities held by ChaChaCha and other affiliates.  This amount includes 284,891 shares of Class B Common Stock held by an affiliate of Mr. Palihapitiya, which are convertible into shares of Class A Common Stock on a one-for-one basis.
    Item 5(c) of the Schedule 13D is hereby amended and supplemented by the following:
    Except as set forth below, none of the Reporting Persons has effected any transactions in the Class A Common Stock since May 8, 2021.
    On June 25, 2021, an affiliate of Mr. Osborne sold 1,342,099 shares of Class A Common Stock in the open market at a weighted average price of $13.0849 per share.
    On June 28, 2021, an affiliate of Mr. Osborne sold 2,909,616 shares of Class A Common Stock in the open market at a weighted average price of $12.8225 per share.
    On June 29, 2021, an affiliate of Mr. Osborne sold 748,285 shares of Class A Common Stock in the open market at a weighted average price of $13.3925 per share.
    On July 7, 2021, the Sponsor distributed its 20,500,000 shares of Class A Common Stock and 10,933,333 warrants to purchase Class A Common Stock to its members on a pro rata basis, including 16,912,500 shares and 9,020,000 warrants distributed to ChaChaCha, and 3,587,500 shares and 1,913,333 warrants distributed to an entity affiliated with Mr. Osborne.  The warrants had an exercise price of $11.50 per share.
    On August 16, 2021, ChaChaCha exercised all of its warrants in a "Make-Whole Exercise" prior to a redemption of such warrants by the Issuer. Pursuant to the terms of the warrants relating to a Make-Whole Exercise, the warrants held by ChaChaCha were exercised for 2,245,980 shares of Class A Common Stock.
    On August 20, 2021, an entity affiliated with Mr. Osborne exercised all of its warrants in the "Make-Whole Exercise" described above. Pursuant to the terms of the warrants relating to a Make-Whole Exercise, these warrants were exercised for 476,419 shares of Class A Common Stock.
    On August 20, 2021, each of ChaChaCha and an entity affiliated with Mr. Osborne distributed 750,000 and 250,000 shares of Class A Common Stock, respectively, for no value.
    On November 22, 2021, SC Master Holdings, LLC ("SC Master"), an entity affiliated with Mr. Palihapitiya, purchased 1,739,130 shares of Class A Common Stock at a price of $5.75 per share in a registered offering by the Issuer (the "Offering").  The funds used to purchase such shares came from SC Master's working capital.

    Item 5(e) of the Schedule 13D is hereby amended and supplemented by the following:

    As of July 7, 2021, the Sponsor ceased to beneficially own more than five percent of the outstanding shares of Class A Common Stock.

    As of August 6, 2021, Mr. Osborne ceased to beneficially own more than five percent of the outstanding shares of Class A Common Stock.



    Item 7. Material to be Filed as Exhibits
     
    Item 7 of the Schedule 13D is hereby amended and supplemented by the following:

         
    Exhibit
    Number
      
    Description
       
    6
      
    Joint Filing Agreement, dated as of January 14, 2022, by and among the Reporting Persons.


    SIGNATURES
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     

    Date: January 14, 2022
    SCH SPONSOR III LLC
         
     
    By:
    /s/ Chamath Palihapitiya
     
    Name:  
    Chamath Palihapitiya
     
    Title:
    Chief Executive Officer
         
         
     
    ChaChaCha SPAC C LLC
         
     
    By:
     /s/ Chamath Palihapitiya
     
    Name:  
     Chamath Palihapitiya
     
    Title:
     Manager
         
         
     
    Chamath Palihapitiya
         
     
    /s/ Chamath Palihapitiya
         
     
    Ian Osborne
         
     
    /s/ Ian Osborne


    Get the next $CLOV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLOV

    DatePrice TargetRatingAnalyst
    12/17/2024$6.00Buy
    Craig Hallum
    10/7/2024$4.00Neutral
    UBS
    2/25/2022$3.00 → $2.50Market Perform
    SVB Leerink
    2/2/2022$7.00 → $3.00Underperform → Market Perform
    Cowen & Co.
    2/2/2022$6.00Buy
    Canaccord Genuity
    1/19/2022$3.00Market Perform
    SVB Leerink
    1/10/2022$9.00 → $3.50Neutral
    Citigroup
    1/7/2022$9.00 → $3.50Neutral → Underperform
    Credit Suisse
    More analyst ratings

    $CLOV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Clover Health Reports First Quarter 2025 Results and Improves Full Year 2025 Guidance

      First quarter 2025 Medicare Advantage membership of 103,418, up 30% year-over-yearFirst quarter 2025 Total revenues of $462 million, up 33% year-over-yearMedicare Advantage medical costs are in line with expectations, underscoring the strength of Clover's technology-first care management modelMeaningful improvement across first quarter 2025 profitability metrics: GAAP Net loss of $1 million, as compared to a GAAP Net loss of $19 million a year agoAdjusted EBITDA of $26 million, up 279% year-over-yearAdjusted Net income of $25 million, up 322% year-over-year Improved Full Year 2025 Guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year

      5/6/25 4:05:00 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Tech That Listens, Learns, and Diagnoses: AI's Breakout Moment in Healthcare

      USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 6, 2025 /PRNewswire/ -- Healthcare is quickly evolving into a digital-first operation, where top executives in the sector are doubling down on artificial intelligence, automation and analytics to reduce costs and improve billing accuracy. This is according to results of a survey from Everest Group (and supported by Omega Healthcare), which showed 85% of senior healthcare executives believe AI will improve efficiencies over the next five years. Now that multitasking AI Agents are being referred to as hospitals' newest "employees", AI-powered electronic noses are detecting scents for health and enviro

      5/6/25 9:45:00 AM ET
      $AMZN
      $CLOV
      $TDOC
      Catalog/Specialty Distribution
      Consumer Discretionary
      Medical Specialities
      Health Care
    • Primary Care Physician Use of Counterpart Assistant Technology Associated with Better Health Outcomes in Patients with Congestive Heart Failure

      WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a wholly owned subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company") and a leading AI-powered physician-enablement platform, today released research demonstrating how Counterpart Assistant ("CA") use is associated with better management of congestive heart failure ("CHF"). The analysis, titled "Driving Clinical Excellence in Chronic Disease: Counterpart Assistant's Role in Heart Failure Care," details the significant positive association among CHF patients between better clinical care and lower hospitalizations, and having a relationship with a PC

      5/1/25 4:30:00 PM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

      The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

      6/20/24 6:36:05 PM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Kuipers Peter J. was granted 326,647 shares, increasing direct ownership by 5% to 6,349,973 units (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      5/21/25 4:10:12 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • General Counsel & Secretary Soares Karen covered exercise/tax liability with 5,345 shares, decreasing direct ownership by 0.42% to 1,262,436 units (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      5/15/25 4:14:58 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Chief Executive Officer Toy Andrew covered exercise/tax liability with 85,535 shares, decreasing direct ownership by 0.78% to 10,868,997 units (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      5/12/25 4:31:41 PM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Financials

    Live finance-specific insights

    See more
    • Clover Health Reports First Quarter 2025 Results and Improves Full Year 2025 Guidance

      First quarter 2025 Medicare Advantage membership of 103,418, up 30% year-over-yearFirst quarter 2025 Total revenues of $462 million, up 33% year-over-yearMedicare Advantage medical costs are in line with expectations, underscoring the strength of Clover's technology-first care management modelMeaningful improvement across first quarter 2025 profitability metrics: GAAP Net loss of $1 million, as compared to a GAAP Net loss of $19 million a year agoAdjusted EBITDA of $26 million, up 279% year-over-yearAdjusted Net income of $25 million, up 322% year-over-year Improved Full Year 2025 Guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year

      5/6/25 4:05:00 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Clover Health to Report First Quarter 2025 Financial Results on May 6, 2025

      WILMINGTON, Del., April 08, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will report first quarter 2025 financial results after market close on Tuesday, May 6, 2025. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on May 6, 2025, to discuss Clover Health's first quarter 2025 business and financial results. First Quarter 2025 Conference Call and Webcast Details: What: Clover Health's First Quarter 2025 Earnings Conference CallWhen: Tuesday, May 6, 2025, at 5:00 p.m. Eastern TimeDial In: To access the call via telephone please dial 800-274-8461 (for U.S. callers) or

      4/8/25 4:05:00 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Clover Health Reports Fourth Quarter and Full Year 2024 Results; Provides Full Year 2025 Guidance

      Full year 2024 GAAP Net loss from continuing operations improves by $164 million year-over-year Full year 2024 Adjusted EBITDA of $70 million, representing an increase of $112 million year-over-year Company well positioned to invest in membership growth and Clover Assistant technology, while maintaining strong profitability Issues full year 2025 guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year at the midpointInsurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpointAdjusted EBITDA profitability between $45 million and $70 millionAdjusted Net income between

      2/27/25 4:05:00 PM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    SEC Filings

    See more
    • Clover Health Investments Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

      5/14/25 8:59:21 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Clover Health Investments Corp.

      10-Q - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

      5/9/25 8:05:31 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • Clover Health Investments Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

      5/6/25 4:06:54 PM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Clover Health with a new price target

      Craig Hallum initiated coverage of Clover Health with a rating of Buy and set a new price target of $6.00

      12/17/24 8:33:41 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • UBS initiated coverage on Clover Health with a new price target

      UBS initiated coverage of Clover Health with a rating of Neutral and set a new price target of $4.00

      10/7/24 7:45:42 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • SVB Leerink reiterated coverage on Clover Health Investments with a new price target

      SVB Leerink reiterated coverage of Clover Health Investments with a rating of Market Perform and set a new price target of $2.50 from $3.00 previously

      2/25/22 5:03:33 AM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

      SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

      11/12/24 2:31:31 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

      SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

      11/4/24 11:25:56 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Clover Health Investments Corp. (Amendment)

      SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

      7/7/23 4:35:52 PM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Garipalli Vivek bought $999,596 worth of shares (531,700 units at $1.88), increasing direct ownership by 61% to 1,409,267 units (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      8/13/24 4:06:53 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Director Garipalli Vivek bought $1,000,426 worth of shares (877,567 units at $1.14) (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      6/20/24 4:03:32 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Loengard Anna U bought $25,672 worth of shares (27,085 units at $0.95) (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      5/20/24 6:57:29 PM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Leadership Updates

    Live Leadership Updates

    See more
    • Clover Health Appoints Industry Veteran as Chief Medical Officer of Medicare Advantage

      WILMINGTON, Del., April 07, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced the appointment of Dr. Shelly Gupta as Chief Medical Officer ("CMO"). Dr. Gupta will oversee Clover's innovative clinical operations, quality initiatives, pharmacy operations, and precision-based chronic disease management programs, directly focusing on patient choice, provider autonomy, and delivering transparent, value-driven healthcare. Dr. Gupta brings extensive healthcare experience to Clover as a trained family practice physician with over a decade of experience in Medicare Advantage leadership and a proven record of enhanc

      4/7/25 4:05:00 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Counterpart Health Names David Tsay M.D., Ph.D as Chief Medical Officer

      FRANKLIN, Tenn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a leading AI-powered physician enablement platform, today announced the appointment of David Tsay M.D., Ph.D as Chief Medical Officer (CMO). Dr. Tsay will play a key role in advancing Counterpart's clinical strategy and product roadmap for Counterpart Assistant, the company's proprietary AI-powered physician enablement software platform that empowers providers to deliver high-quality, cost-effective care. Counterpart is a subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"). David Tsay is a distinguished physician executive with deep expertise and over two decades of ex

      10/8/24 6:15:00 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • Clover Health Appoints Seasoned Healthcare Executive as Chief Operating Officer for Medicare Advantage Operations

      FRANKLIN, Tenn., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health" or "Clover"), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced the appointment of Joseph Brand as Chief Operating Officer (COO) for its Medicare Advantage (MA) plan. Mr. Brand will oversee core MA operations and drive performance improvements, with a focus on improving healthcare delivery in New Jersey by leveraging operational efficiencies and technological innovation. Mr. Brand brings nearly 20 years of healthcare leadership experience, having held prominent positions in healthcare operation

      9/26/24 4:00:00 PM ET
      $CLOV
      Medical Specialities
      Health Care